DUX4 and the P53 pathway in FSHD pathogenesis

DUX4 和 P53 通路在 FSHD 发病机制中的作用

基本信息

项目摘要

DESCRIPTION (provided by applicant): Facioscapulohumeral muscular dystrophy (FSHD) was linked to contractions in the number of D4Z4 repeats on chromosome 4q35 two decades ago. These contractions do not completely remove or mutate any genes, and solving the central mystery of how they lead to FSHD has been the most critical need in the field since this genetic abnormality was discovered. Recent work provides hope that the pathogenic mechanisms are coming into focus. Several published studies, including ours, support an FSHD pathogenesis model involving over- expression of the D4Z4-localized DUX4 gene, which encodes a transcription factor. These findings have sharpened the focus of the FSHD field, and there is now growing momentum to understand DUX4 biology and the mechanisms by which it may contribute to FSHD development. In our initial work, we demonstrated the myopathic potential of DUX4 in animal muscle, and showed that DUX4 toxicity was dependent upon its ability to bind DNA and activate p53-dependent cell death pathways. In this proposal, we will test several hypotheses addressing the mechanistic role of DUX4 and the p53 pathway in FSHD pathogenesis. These studies will help define the pathogenic insults underlying FSHD, which is ultimately necessary for therapeutic development.
描述(由申请人提供):面肩肱型肌营养不良症(FSHD)与20年前染色体4q35上D4Z4重复序列数量的收缩有关。这些收缩不会完全消除或突变任何基因,并且解决它们如何导致FSHD的核心谜团一直是该领域最关键的需求,因为这种遗传异常被发现。最近的工作提供了希望,致病机制正在成为焦点。包括我们在内的几项已发表的研究支持FSHD发病机制模型,该模型涉及D4Z4定位的DUX4基因的过度表达,DUX4基因编码一种转录因子。这些发现使FSHD领域的焦点更加突出,现在越来越多的人开始了解DUX4生物学及其可能有助于FSHD发展的机制。在我们最初的工作中,我们证明了DUX4在动物肌肉中的肌病潜力,并表明DUX4毒性取决于其结合DNA和激活p53依赖性细胞死亡途径的能力。在这个建议中,我们将测试几个假设解决机制的作用DUX4和p53通路在FSHD发病机制。这些研究将有助于确定FSHD潜在的致病性损伤,这是治疗发展的最终必要条件。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Scott Q Harper其他文献

Scott Q Harper的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Scott Q Harper', 18)}}的其他基金

CRISPR-Cas13 gene therapy and RNA editing for Facioscapulohumeral muscular dystrophy (FSHD)
面肩肱型肌营养不良症 (FSHD) 的 CRISPR-Cas13 基因治疗和 RNA 编辑
  • 批准号:
    10469571
  • 财政年份:
    2021
  • 资助金额:
    $ 32.08万
  • 项目类别:
Chromatin remodeling gene therapy for FSHD using split-vector AAV SMCHD1 vectors
使用分裂载体 AAV SMCHD1 载体进行 FSHD 染色质重塑基因治疗
  • 批准号:
    10288435
  • 财政年份:
    2021
  • 资助金额:
    $ 32.08万
  • 项目类别:
CRISPR-Cas13 gene therapy and RNA editing for Facioscapulohumeral muscular dystrophy (FSHD)
面肩肱型肌营养不良症 (FSHD) 的 CRISPR-Cas13 基因治疗和 RNA 编辑
  • 批准号:
    10298500
  • 财政年份:
    2021
  • 资助金额:
    $ 32.08万
  • 项目类别:
Chromatin remodeling gene therapy for FSHD using split-vector AAV SMCHD1 vectors
使用分裂载体 AAV SMCHD1 载体进行 FSHD 染色质重塑基因治疗
  • 批准号:
    10451651
  • 财政年份:
    2021
  • 资助金额:
    $ 32.08万
  • 项目类别:
CRISPR-Cas13 gene therapy and RNA editing for Facioscapulohumeral muscular dystrophy (FSHD)
面肩肱型肌营养不良症 (FSHD) 的 CRISPR-Cas13 基因治疗和 RNA 编辑
  • 批准号:
    10663880
  • 财政年份:
    2021
  • 资助金额:
    $ 32.08万
  • 项目类别:
In vivo efficacy studies to support the development of DUX4-targeted RNAi therapy for FSHD
体内功效研究支持开发 DUX4 靶向 RNAi 治疗 FSHD
  • 批准号:
    9299936
  • 财政年份:
    2017
  • 资助金额:
    $ 32.08万
  • 项目类别:
In vivo efficacy studies to support the development of DUX4-targeted RNAi therapy for FSHD
体内功效研究支持开发 DUX4 靶向 RNAi 治疗 FSHD
  • 批准号:
    9978927
  • 财政年份:
    2017
  • 资助金额:
    $ 32.08万
  • 项目类别:
Project 2: DUX4 inhibition with non-coding RNAs as a therapeutic strategy for facioscapulohumeral muscular dystrophy (FSHD)
项目 2:用非编码 RNA 抑制 DUX4 作为面肩肱型肌营养不良症 (FSHD) 的治疗策略
  • 批准号:
    10017026
  • 财政年份:
    2016
  • 资助金额:
    $ 32.08万
  • 项目类别:
DUX4 inhibition as a therapeutic strategy for FSHD
DUX4 抑制作为 FSHD 的治疗策略
  • 批准号:
    8442833
  • 财政年份:
    2012
  • 资助金额:
    $ 32.08万
  • 项目类别:
DUX4 and the P53 pathway in FSHD pathogenesis
DUX4 和 P53 通路在 FSHD 发病机制中的作用
  • 批准号:
    8900757
  • 财政年份:
    2012
  • 资助金额:
    $ 32.08万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 32.08万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 32.08万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 32.08万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 32.08万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 32.08万
  • 项目类别:
    Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 32.08万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 32.08万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 32.08万
  • 项目类别:
    EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 32.08万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 32.08万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了